Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-12-26
2006-12-26
Badio, Barbara P. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C540S107000, C540S109000, C540S112000
Reexamination Certificate
active
07153844
ABSTRACT:
wherein X may be —CH2—O—CH2— or —CH2—, wherein n may be 1, 2, 3, 4 or 5 when X is —CH2—O—CH2—, wherein n may be 2, 3, 4, 5, 6, 7, 8, 9 or 10 when X is —CH2—, wherein o may be 1, 2 or 3, wherein Y may be O or 17β-OH, where the dotted line represents the presence or absence of a second chemical bond,wherein R1may be selected from the group consisting of H, straight alkyl groups of 1 to 5 carbon atoms, and branched alkyl groups of 3 to 5 carbon atoms,wherein R2may be selected for the group consisting of H, straight alkyl groups of 1 to 4 carbon atoms, branched alkyl groups of 3 or 4 carbon atoms, F, Cl, Br, I, —CF3, —NO2, —OR1, where R1is as defined hereinabove, —COR1, where R1is as defined hereinabove, and —CH2OH. These compounds possess anticancer activity against hormono-dependent breast, uterus as well as ovarian cancers.
REFERENCES:
E. Wong and C.M. Giandomenico << Current Status of Platinum-Based Antitumor Drugs >>, Chemical Review, 99, 2451-2466 (1999).
E.R. Jamieson and S.J. Lippard, << Structure, Recognition, and Processing of Cisplatin-DNA Adducts >> Chemical Review, 99 2499-2510 (1999).
J. Reedijk, <<Why Does Cisplatin Reach Guanine-N7 with Competing S-Donor Ligands Available in the Cell?>>, Chemical Review, 99, 2499-2510 (1999).
Tremblay, R. , S. Auge rand D. PoirierSynthetic Communications, 25, 2483-2495 (1995).
Tedesco, R., R. Fiaschi and E. NapolitanoSynthesis, 12, 1493-1495 (1995).
W..C. Still, M. Kahn and A. Mitra, J. Org. Chem., 43, 2923 (1978).
Y. He, S. Groleau, R.C.-Gaudreault, M. Caron, H.-H. Thérien, G. Bérubé, Bioorganic & Medicinal Chemistry Letters, 19, 2217-2222 (1995).
J. Charmichael et al. (Cancer Res. 47, 943-946 (1987).
C.H.J. Ford et al., Cancer Chemother. Pharmacol. 24, 295-301 (1986).
Alley, M. C. et al (Cancer Research. No. 46, 589-601, 1987.
Boyd, M.R. & Paull, K.D. (Drug Development Research. 34, 91-109, (1995)).
Badio Barbara P.
Berube Gervais
Ogilvy Renault LLP
LandOfFree
Estrogen-linked platinum (II) complexes as anticancer agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Estrogen-linked platinum (II) complexes as anticancer agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Estrogen-linked platinum (II) complexes as anticancer agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3658533